Organ-on-a-Chip Resources

The Human Touch: Primary Human Microphysiological Systems for Testing HSD17B13 Inhibitors

Webinar Series 5 Episode 4

In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets.

The Dash for NASH: How To Succeed in NASH Therapeutic Development

Webinar Series 5 Episode 3

Find out how to: rapidly adopt an organ-on-a-chip (OOC) approach to NASH research, generate clinically translatable data from an industry-proven in vitro NASH model, and how OOC can help you unlock NASH disease mechanisms, and confirm drug efficacy and safety.

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Kostrzewski et al

As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks.

Pros and cons of preclinical models of Non-Alcoholic Steatohepatitis

This infographic was made by Biotechniques to help educate people on our NASH-in-a-box kit and how it sets a new standard in the search for an approved NASH therapeutic.

In Focus: Modeling NASH disease – organ-on-a-chip technologies

This short animation describes how our NASH-in-a-box kit enhances your chance of successfully developing NASH therapeutics by recreating our industry-proven NASH model in your laboratory. Created by Biotechniques.

Organ-on-a-Chip Models of Fatty Liver Disease

15-Minute Tech Blast – In this podcast developed by Biotechniques, our Lead Scientist Gareth Guenigault discussed NAFLD & NASH and their growing prevalence both in terms of cases and economic factors.

New Model Will Support Drug Discovery for Liver Disease NASH

Dr Audrey Doubourg discusses the therapeutic challenges of NASH and how our NASH-in-a-box kit will help to advance drug discovery.

This article is taken from Technology Networks, April 2022.

A pressing Need for Accurate Preclinical Models of Metabolic Disease

How using organ-on-a-chip (OOC) can more accurately recapitulate the physiology and functions of the human body by culturing under flow perfusion – to mimic the blood – in 3D.

This article is taken from European Biopharmaceutical Review January 2022, pages 28-31.

β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development

Rao et al., 2021

This study shows the effect of the presence of β2-spectrin (SPTBN1) in the promotion of sterol regulatory element (SRE)–binding protein (SREBP)–stimulated lipogenesis. These findings suggest SPTBN1 could be a potential target for a therapeutic against NASH and liver cancer.

Hype or hope – microphysiological systems?

This article in DDW examines MPS (microphysiological systems/organ-on-a-chip) in drug discovery and their place in the preclinical ‘toolbox’.

This article is taken from Drug Discovery World, October 2021.

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system

Kostrzewski et al., 2021

It was shown in this study that the MPS NASH model, composed of a primary cell co-culture in various conditions, is able to model different characteristics of clinical NASH, including advanced disease with a quantifiable fibrosis phenotype as well as pharmaceutical intervention.

Of Mice and Men – Will human organ-on-a-chip disease models replace animal use?

The aim of organ-on-a-chip (OOC) technology is to more accurately replicate human physiology in vitro to overcome the relevance limitations of current approaches, and the field is progressing at a rapid pace!